The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  2005-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00213-004-1999-zPMID 15316717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• S100B Serum Levels and Long-Term Improvement of Negative Symptoms in Patients with Schizophrenia

  2004cited by this paper
• Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.

  2004cited by this paper
• The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.

  2004cited by this paper
• S100B in brain damage and neurodegeneration

  2003influential reference
• S100B and response to treatment in major depression: a pilot study.

  2003influential reference
• Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression.

  2002cited by this paper
• Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.

  2002cited by this paper
• S100B is increased in mood disorders and may be reduced by antidepressive treatment

  2002cited by this paper
• The cellular neurobiology of depression

  2001cited by this paper
• The impact of transcranial magnetic stimulation on cognitive processing: an event-related potential study

  2001cited by this paper
• Neurotrophic factor S100 beta in major depression.

  2001cited by this paper
• S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.

  2001influential reference
• Event-related potentials: Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?

  2001cited by this paper
• S-100B is increased in melancholic but not in non-melancholic major depression.

  2001cited by this paper
• Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology

  2001cited by this paper
• Increased serum S100B protein in schizophrenia: a study in medication-free patients.

  2001cited by this paper
• Neurotrophic Factor S100beta in Major Depression

  2001cited by this paper
• A study of P300-event related evoked potential in the patients of major depression.

  1999cited by this paper
• Dynamic Changes of Cognitive Habituation and Serotonin Metabolism During the Migraine Interval

  1999cited by this paper
• Visual cognitive dysfunction in depression: an event-related potential study.

  1998cited by this paper
• Auditory event related potentials in major depression: prolonged P300 latency and increased P200 amplitude.

  1998cited by this paper
• Changes in auditory P300 in patients with major depression and silent cerebral infarction.

  1997cited by this paper
• Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression.

  1996cited by this paper
• Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder.

  1995cited by this paper
• Event-related potentials and psychopharmacology. Cholinergic modulation of P300.

  1994cited by this paper
• P300 amplitude in non-bipolar, melancholic depression.

  1993cited by this paper
• P300 brain activity in seizure patients preceding temporal lobectomy.

  1991cited by this paper
• Event-related potentials in depression: influence of task, stimulus hemifield and clinical features on P3 latency.

  1991cited by this paper
• Changes in Auditory P3 Event-related Potential in Schizophrenia and Depression

  1987cited by this paper
• A subcortical correlate of P300 in man.

  1984cited by this paper
• The hippocampal formation as a source of the slow endogenous potentials.

  1983cited by this paper
• Endogenous potentials generated in the human hippocampal formation and amygdala by infrequent events.

  1980cited by this paper
• The scalp topography of potentials in auditory and visual discrimination tasks.

  1977cited by this paper
• Development of a rating scale for primary depressive illness.

  1967cited by this paper

• Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?

  2024cites this paper
• Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder.

  2023cites this paper
• Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review

  2023influential citation
• Entzündliche Grundlagen neuropsychiatrischer Störungen

  2022cites this paper
• Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential

  2022cites this paper
• High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers

  2022cites this paper
• Neuroanatomical Findings in Bipolar Disorder

  2021cites this paper
• An Overview of Machine Learning Applications in Mood Disorders

  2021cites this paper
• Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders

  2021cites this paper
• Functional Connectome in Bipolar Disorder

  2021cites this paper
• fMRI Neurofeedback as Treatment for Depression

  2021cites this paper
• Correlation between S100B and severity of depression in MDD: A meta-analysis

  2021cites this paper
• Peripheral biomarkers in major depressive disorders

  2021cites this paper
• Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

  2021cites this paper
• Imaging Genetic and Epigenetic Markers in Mood Disorders

  2021cites this paper
• Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder

  2021cites this paper
• Resting-State Functional Connectivity in Unipolar Depression

  2021cites this paper
• Effects of Lithium on Brain Structure in Bipolar Disorder

  2021cites this paper
• Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders

  2021cites this paper
• Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders

  2021cites this paper
• Functional Near-Infrared Spectroscopy Studies in Mood Disorders

  2021cites this paper
• Electrophysiological Biomarkers for Mood Disorders

  2021cites this paper
• Inflammation‐driven brain and gut barrier dysfunction in stress and mood disorders

  2021cites this paper
• Neuroimaging Brain Inflammation in Mood Disorders

  2021cites this paper
• Brain Imaging and the Mechanisms of Antidepressant Action

  2021cites this paper
• Neuroimaging Studies of Effects of Psychotherapy in Depression

  2021cites this paper
• Magnetoencephalography Studies in Mood Disorders

  2021cites this paper
• Brain Imaging Methods in Mood Disorders

  2021cites this paper
• Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus

  2021cites this paper
• Neuroimaging Biomarkers in Pediatric Mood Disorders

  2021cites this paper
• Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study

  2020cites this paper
• S100 calcium-binding protein B in older patients with depression treated with electroconvulsive therapy.

  2019cites this paper
• Astrocytic plasticity at the dorsal dentate gyrus on an animal model of recurrent depression.

  2019cites this paper
• Serum S100B levels in patients with depression

  2019cites this paper
• Neural Circuits and Electroencephalography-Based Neurobiology for Depression

  2019cites this paper
• On Neuroimmunology and Brain Function: Experimental and Clinical Studies

  2019cites this paper
• Does S100B have a potential role in affective disorders? A literature review

  2018cites this paper
• S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms

  2018cites this paper
• Emotion Processing by ERP Combined with Development and Plasticity

  2017cites this paper
• Diagnostik und Therapie depressiver Störungen

  2017cites this paper
• Stem Cell Factor (SCF) is a putative biomarker of antidepressant response

  2016cites this paper
• Glial cells as key elements in the pathophysiology and treatment of bipolar disorder

  2016cites this paper
• Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model

  2016cites this paper
• Review on EEG and ERP predictive biomarkers for major depressive disorder

  2015cites this paper
• S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression

  2015cites this paper
• First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression

  2015influential citation
• Targeting astrocytes in major depression

  2015cites this paper
• Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors

  2014cites this paper
• The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of antidepressant treatment in patients with chronic viral hepatitis: a prospective study.

  2014cites this paper
• S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence.

  2013cites this paper
• Antidepressants act directly on astrocytes: evidences and functional consequences.

  2013cites this paper
• Serum S100B Represents a New Biomarker for Mood Disorders

  2013cites this paper
• Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.

  2013cites this paper
• The neurobiology of the EEG biomarker as a predictor of treatment response in depression.

  2012cites this paper
• Surrogate markers of treatment outcome in major depressive disorder.

  2012cites this paper
• Cerebrospinal fluid S100B levels reflect symptoms of depression in patients with non-inflammatory neurological disorders.

  2012cites this paper
• Glial pathology is modified by age in mood disorders--a systematic meta-analysis of serum S100B in vivo studies.

  2011cites this paper
• The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants

  2011cites this paper
• Astrocytes in Major Depressive Disorder and Schizophrenia: Pathophysiological and Therapeutic Aspects

  2011cites this paper
• Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

  2010cites this paper
• Serum S100B: A Potential Biomarker for Suicidality in Adolescents?

  2010cites this paper
• Neuropsychiatric disorders related to interferon and interleukins treatment

  2009cites this paper
• Neonatal S100B Protein Levels After Prenatal Exposure to Selective Serotonin Reuptake Inhibitors

  2009cites this paper
• Circulating Cerebral S100B Protein Is Associated with Depressive Symptoms following Myocardial Infarction

  2009cites this paper
• S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

  2009cites this paper
• S100B as a Potential Neurochemical Biomarker in a Variety of Neurological, Neuropsychiatric and Neurosurgical Disorders

  2009cites this paper
• Lectures

  2008cites this paper
• Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia.

  2008cites this paper
• Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin.

  2008cites this paper
• The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression

  2008influential citation
• Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response

  2008cites this paper
• Serum markers support disease-specific glial pathology in major depression.

  2008cites this paper
• Serum S100B but not NSE Levels are Increased in Morbidly Obese Individuals Affected by Obstructive Sleep Apnea–Hypopnea Syndrome

  2008cites this paper
• Serum S100B and antioxidant enzymes in bipolar patients.

  2007cites this paper
• Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled Trial With Mirtazapine

  2007cites this paper
• Kynurenine pathway in major depression: evidence of impaired neuroprotection.

  2007cites this paper
• The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features.

  2007cites this paper
• Neurochemistry immune systems interaction in depression

  2007cites this paper
• Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment.

  2007cites this paper
• Could treatment with arundic acid (ONO-2506) increase vulnerability for depression?

  2006cites this paper
• Opposite effects of depression and antidepressants on processing speed and error rate.

  2006cites this paper
• Olanzapine and S100 Proteins

  2006cites this paper
• Current awareness in human psychopharmacology.

  2005cites this paper
• Current awareness in human psychopharmacology

  2005cites this paper